Education
About Us
Working with TipRanks
Follow Us
Neuropace, Inc. (NPCE)
:NPCE
NPCE Stock Chart & Stats
$12.94
-$0.66(-5.31%)
At close: 4:00 PM EST
$12.94
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)196.17K
Market Cap
$431.34M
Enterprise Value$352.78M
Total Cash (Recent Filing)$60.01M
Total Debt (Recent Filing)$71.18M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 10, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding33,307,735
10 Day Avg. Volume330,440
30 Day Avg. Volume196,171
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)40.67
Price to Sales (P/S)4.08
P/FCF Ratio-17.85
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue3.72
Enterprise Value/Gross Profit4.84
Enterprise Value/Ebitda-23.27
Forecast
1Y Price Target
$18.00Price Target Upside39.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$95.66M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNeuroPace reported its 3Q25 financial results with total revenue of $27.4M, representing 29.9% YoY growth and beating projections.
Regulatory ProgressFDA discussions for IGE are progressing well, with an expected accelerated review timeline following PMA supplement submission.
Revenue GuidanceManagement has increased FY2025 revenue guidance to $97-98M with a gross margin of 76-77%.
Bears Say
Clinical Study ResultsThe study did not reach statistical significance for the primary effectiveness endpoint, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group.
Distribution AgreementNeuroPace has decided not to renew the distribution agreement with DIXI Medical, impacting revenue projections.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $431.34M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 110 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.085.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 33,307,735 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 38.085%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (39.10% Upside)
$18.00 (39.10% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.47%
12-Months-Change
Fundamentals
Return on Equity
-169.27%
Trailing 12-Months
Asset Growth
11.37%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. is a medical technology company focused on developing innovative solutions for neurological disorders, particularly epilepsy. The company operates within the healthcare sector, specializing in the design, manufacturing, and commercialization of neuromodulation devices. Its flagship product, the RNS System, is an implantable device that monitors and responds to abnormal electrical activity in the brain to prevent seizures in patients with drug-resistant epilepsy. NeuroPace aims to improve the quality of life for patients through advanced neurostimulation technology.
NPCE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, positive adjusted EBITDA, and increased guidance. There were challenges, including the winding down of the DIXI product line and extended timelines for pediatric indication, but these were outweighed by positive developments and strategic progress.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$18.00
▲(39.10% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
Currently, No data available
---